XGN (Exagen) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGN Exagen Inc XGN
59 GF Score
Price $8.67
GF Value $3.27
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exagen Defensive Interval Ratio?

XGN
59GF Score
Exagen Inc XGN
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $8.67 is trading 165% above its estimated GF Value™ of $3.27. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Defensive Interval Ratio:
  • GF Value™: $3.27 vs. price of $8.67 (165% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc. is a commercial-stage diagnostics company based in the United States that develops and markets blood-based tests for autoimmune and rheumatic diseases. Its flagship AVISE brand includes AVISE CTD, a test intended to aid in the differential diagnosis of connective tissue diseases such as systemic lupus erythematosus, and AVISE Lupus, along with tests used for prognosis and monitoring of disease activity. The company sells primarily to rheumatologists and other specialists through a direct sales force, and it generates revenue mainly from reimbursement by third-party payers, including Medicare, Medicaid, and commercial insurers, for tests performed at its clinical laboratory. Exagen also pursues pharmaceutical and research collaborations. Operations are concentrated in the United States, with its laboratory and corporate functions located in California and additional facilities elsewhere in the country.
59GF Score

Get the complete analysis for XGN

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.67
Price
$3.27
GF Value